Burns & Levinson, in partnership Viridian Capital Advisors, is incredibly excited to announce the first in what it hopes will be an annual event, “The Cannabis Conference: Growth Opportunities for Professionals, Operators and Investors.”
Slated to take place at the Hilton Boston Dedham hotel on Tuesday, October 17th, from 8:00 a.m. to 6:00 p.m., the conference will bring together professional investors, entrepreneurs, thought leaders, and other participants in the cannabis space for an exploration of the industry’s potential opportunities and challenges. The event is by invitation only, and is geared toward those seeking to improve their present position in, or make an initial foray into, the legalized marijuana market.
The program features panels of regional and national experts who will be discussing the following topics:
The New England Experience
Nationwide, the landscape of the legalized marijuana industry has changed significantly in recent years—no place more so than New England. In 2016, Maine and Massachusetts voted to fully legalize cannabis, and Connecticut, New Hampshire, Rhode Island, and Vermont all allow its use for medical purposes. This panel will examine how the industry’s laws and regulations have evolved in the region, focusing on the experiences of operators who have navigated the sometimes tempestuous legal waters to guide their businesses to success and charted paths to raising capital and investments.
Follow the Money: Analyzing Capital Flow into the Legal Cannabis Industry
This panel will focus on the capital infusions necessary to launch, operate, or invest in the cannabis space, with Viridian providing deal-data insight regarding capital raises and M&A activity. Additional topics will include valuations and structures, as well as the involvement (or lack thereof) of certain investor types (e.g., traditional VCs, institutional investors, etc.) and strategic acquirers (e.g., big alcohol, big tobacco, etc.).
Sector Focus: Cannabinoid-Based Biopharmaceuticals and Personalized Medicine
Cannabinoid-based pharmaceuticals and biotechnologies represent a sub-sector of the industry that, could hold the greatest potential value over time. This panel will delve deeply into the research, development, and commercialization of cannabis-based pharmaceuticals, as well as the development of the full data chain needed to create effective personalized medicines from the plant.
The Future of Cannabis
Cannabis is already a multi-billion dollar industry, and its growth is projected to potentially increase at an exponential and possibly unprecedented rate over the coming years. This panel will explore what the future could hold for legalized marijuana, addressing such topics as legal and regulatory changes at the state and federal levels; de- or re-scheduling cannabis under the Controlled Substances Act; changes in interstate and international commerce (i.e., importing/exporting); shifts in business models (e.g., the need for wholesalers, more centralized processing, an additional focus on biotech/pharma, improvements in quality control, the increased value of big data, etc.); and opportunities for investors and capital providers.
We look forward to an interesting, informative day, and are eager to advance the dialogue regarding cannabis in the Commonwealth. If you’d like more information or are interested in attending, please contactRashell Wilson.